Stifel Downgrades Orchard Therapeutics to Hold, Announces $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha has downgraded Orchard Therapeutics (NASDAQ:ORTX) from Buy to Hold and set a price target of $16.
October 05, 2023 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Orchard Therapeutics has been downgraded from Buy to Hold by Stifel with a price target of $16.
The downgrade from Buy to Hold by Stifel indicates a less optimistic outlook for the company's stock in the short term. This could potentially lead to a decrease in the stock's price. The price target of $16 provides a benchmark for investors, which could also influence the stock's price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100